Msos stock forecast 2025 based on current market trends

Based on current market trends, the "MSOS stock forecast 2025" indicates potential upside if U.S. cannabis reform accelerates. Institutional money could flow in, lifting average trading volumes by over 30%, with projected price targets ranging from $12 to $18 per share under moderate growth scenarios. GlobalData’s senior medical analyst Selena Yu foresees Cardinal’s acquisition as reflecting a shift from drug distribution with a “lower profit margin, towards higher margin speciality care in urology”. The company also has a presence in Israel and Germany with its brand Peace Naturals. In late 2023, the company re-entered the German medical cannabis market through its partnership with a German medical cannabis company called Cansativa Group. Cronos serves the Israeli market through its subsidiary Cronos Israel. Portfolio turnover rates are declining, which historically precedes sustained price climbs. This behavior aligns with the optimistically skewed "MSOS stock forecast 2025".